ValuEngine Upgrades Pieris Pharmaceuticals (PIRS) to Hold
ValuEngine upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a research report report published on Friday.
A number of other research firms also recently issued reports on PIRS. HC Wainwright raised their price objective on shares of Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a buy rating in a report on Tuesday, January 16th. William Blair started coverage on shares of Pieris Pharmaceuticals in a report on Wednesday, January 17th. They set an outperform rating for the company. Finally, BidaskClub upgraded shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 27th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Pieris Pharmaceuticals currently has an average rating of Buy and a consensus target price of $10.00.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.40 during mid-day trading on Friday, hitting $8.07. 1,019,168 shares of the stock traded hands, compared to its average volume of 609,586. The stock has a market capitalization of $380.34, a P/E ratio of -11.05 and a beta of -78.08. Pieris Pharmaceuticals has a 52 week low of $1.88 and a 52 week high of $8.34.
In related news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.05% of the company’s stock.
Large investors have recently modified their holdings of the business. Wells Fargo & Company MN bought a new position in Pieris Pharmaceuticals during the third quarter worth about $105,000. Bank of Montreal Can bought a new position in Pieris Pharmaceuticals during the fourth quarter worth about $144,000. Voya Investment Management LLC bought a new position in Pieris Pharmaceuticals during the second quarter worth about $100,000. The Manufacturers Life Insurance Company boosted its position in Pieris Pharmaceuticals by 1,106.3% during the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 29,150 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Pieris Pharmaceuticals by 107.5% in the third quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 17,100 shares during the period. Hedge funds and other institutional investors own 50.77% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.